StockUS listing USCMOPFPINKHealthcareQuality Compounder

Cosmo Pharmaceuticals N.V(CMOPF) Stock Analysis | Healthcare

USD --+0.00%
Reward80High
Risk45Moderate
75%Data
Strong 33% profit margin · Revenue down 62% YoY
USD —+0.00 (+0.00%) Previous close · PINK
Market cap 2.57Bn
Reward Ratingⓘ80 High reward assessment · 75% data coverage
Top 5% of stocksView factors
Risk Ratingⓘ45 Moderate risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on CMOPF to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Cosmo Pharmaceuticals N.V?

focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide.

AI Brief Pro

The brief on Cosmo Pharmaceuticals N.V

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Cosmo Pharmaceuticals N.V?

focuses on the development and commercialization products for gastroenterology, dermatology, and healthtech worldwide. The company offers GI Genius, a computer-assisted system that uses artificial intelligence in real time to detect colorectal lesions; Winlevi, a prescription medicine used on the skin to treat acne vulgaris; Lialda/Mezavant/Mesavancol, a once-daily mesalamine tablet approved to help get active, mild to moderate ulcerative colitis into remission; Uceris/Cortiment, an oral tablet formulation that delivers budesonide directly to the lumen of the colon; Eleview, an injectable composition to allow endoscopists with a faster and less risky excision of gastrointestinal lesions; Lumeblue, a diagnostic drug for the visualisation of colorectal lesions during colonoscopies; Aemcolo/Relafalk, a pharmaceutical drug product in form of tablets that is approved for the treatment of travelers' diarrhoea; and Byfavo, an intravenous benzodiazepine sedative/anesthetic. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 2.57B, and a P/E ratio of 35.9x.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Strong margins and consistent earnings support financial stability.
Risk
Risk profile appears balanced versus broad market conditions.
Valuation
Premium valuation reflects strong growth expectations already priced in.

OpenBook Logo Analysis

Reward: High (80)

Similar stocks to compare

A short list of Drug Manufacturers - General names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - General
P/E Ratio35.9338
Beta1.462
Insider Activity
12M windowNo data
No insider activity data available for this ticker.